Trial reportDiabetes care2020
Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study.
Trial report in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Therapeutic potential of anti-thymocyte globulin in type 1 diabetes: A systematic review.PloS one · 2025Pooled it
- Comprehensive Factors for Predicting the Complications of DiabetesMellitus: A Systematic Review.Current diabetes reviews · 2024Pooled it
- A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.Frontiers in endocrinology · 2022Pooled it
- Association of Time in Range and Time in Tight Range With Cardiovascular Risk Factor Exposure in Youth With Type 1 Diabetes: A Cross-Sectional Analysis on LDL Cholesterol and Blood Pressure Data From the SWEET International Database.Diabetes, obesity & metabolism · 2026Article
- Demographic Change in Prevalent Type 1 Diabetes Adult Population, and Association of Risk Factors With Comorbidities and Mortality-Results From the Finnish Diabetes Control Study FinDiCon.Diabetes, obesity & metabolism · 2026Article
- Associations between body composition and glycemic control: an exploratory analysis of bioelectrical impedance parameters in adolescents with type 1 diabetes.Diabetology & metabolic syndrome · 2026Article
- Impact of early and tight HbA1c control on the risk of long-term complications and cardiovascular death in patients with type 2 diabetes from the Swedish National Diabetes Register.Diabetes, obesity & metabolism · 2026Article
- The discordance of remnant cholesterol and low-density lipoprotein cholesterol as a predictor of diabetes, diabetic microvascular diseases, and cardiovascular disease.Diabetology & metabolic syndrome · 2026Article
- Heart Failure in Type 1 vs. Type 2 Diabetes Mellitus: Shared Pathways, Distinct Challenges.Journal of diabetes research · 2026Review
- Trends in cardiovascular disease prevalence among adults with type 1 diabetes in the USA: analysis of commercial claims data, 2017-2021.BMJ open diabetes research & care · 2025Article
- Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality.European heart journal · 2025Article
- The NIDDK Takes on the Complications of Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.Diabetes care · 2025Review
- Cardiovascular disease in women with type 1 diabetes: a narrative review and insights from a population-based cohort analysis.Cardiovascular diabetology · 2025Review
- Age-specific differences in association of glycosylated hemoglobin levels with the prevalence of cardiovascular diseases among nondiabetics: the National Health and Nutrition Examination Survey 2005-2018.BMC cardiovascular disorders · 2024Article
- Association of Urine Albumin to Creatinine Ratio With Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus.The Journal of clinical endocrinology and metabolism · 2024Article
- Risk estimation for recurrent cardiovascular events using the SMART-REACH model and direct inpatient cost profiling in Indonesian ASCVD patients: a large-scale multicenter study.Frontiers in cardiovascular medicine · 2024Article
- Article
- Epidemiology of the first-ever cardiovascular event in people with type 1 diabetes: a retrospective cohort population-based study in Catalonia.Cardiovascular diabetology · 2023Article
- Carbohydrate counting as a strategy to optimize glycemic control in type 1 diabetes mellitus.Archives of endocrinology and metabolism · 2023Article
- Type 1 diabetes management: Room for improvement.Journal of diabetes · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 2 countries.
Funding
Abstract
objectiveThe Diabetes Control and Complications Trial (DCCT) and its observational follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) demonstrated the dominant role of glycemia, second only to age, as a risk factor for a first cardiovascular event in type 1 diabetes (T1D). We now investigate the association between established risk factors and the total cardiovascular disease (CVD) burden, including subsequent (i.e., recurrent) events. RESEARCH DESIGN AND
methodsCVD events in the 1,441 DCCT/EDIC participants were analyzed separately by type (CVD death, acute myocardial infarction [MI], stroke, silent MI, angina, percutaneous transluminal coronary angioplasty/coronary artery bypass graft [PTCA/CABG], and congestive heart failure [CHF]) or as composite outcomes (CVD or major adverse cardiovascular events [MACE]). Proportional rate models and conditional models assessed associations between risk factors and CVD outcomes.
resultsOver a median follow-up of 29 years, 239 participants had 421 CVD events, and 120 individuals had 149 MACE. Age was the strongest risk factor for acute MI, silent MI, stroke, and PTCA/CABG, while glycemia was the strongest risk factor for CVD death, CHF, and angina, second strongest for acute MI and PTCA/CABG, third strongest for stroke, and not associated with silent MI. HbA
conclusionsIntensive glycemic management is recommended to lower the risk of initial CVD events in T1D. After a first event, optimal glycemic control may reduce the risk of recurrent CVD events and should be maintained.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.